SABCS: Some Older Women With Breast Cancer May Opt to Skip RT
Local recurrence increased but overall survival at 10 years similar with omission of RT in older women with HR+ breast cancer.
Conference News
Most Patients With Local or Regional Prostate Cancer Die From Other Causes
Understanding causes of death in contemporary patients with prostate cancer is essential for proper survivorship management, according to investigators.
Hospitalization Burden of Patients with Multiple Myeloma
Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.
BCG Induction Timing After TURBT Does Not Affect Therapeutic Response
Patients who received BCG induction within 3 weeks or 3 weeks or more after surgery for nonmuscle-invasive bladder cancer did not differ in their rates of BCG intolerance and recurrence- and progression-free survival, a study found.
Fixed Duration Ibrutinib-Venetoclax for CLL Resulted in High Rate of Undetectable MRD
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
Mortality Rates, Diverse Causes of Death in Polycythemia Vera
Study results presented at the annual meeting of the American Society of Hematology suggest that the estimated 4-year mortality rate among patients with polycythemia vera is more than 10%, and that causes of death vary.
Prior Radiation Linked to Worse Survival in Bladder Cancer Cases
This study examined bladder cancer that developed after radiation for any cancer potentially affecting the organ, not just prostate cancer.
Response Rates in Phase 1 Studies of Hematologic Malignancies Improved Over Time
Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.
Gene Therapy for NMIBC Effective Regardless of Patient Characteristics
In a subgroup analysis, neither patient characteristics nor prior treatment history influenced response to a novel intravesical gene therapy for BCG-unresponsive bladder cancer.
Apalutamide Could Reduce Prostate Cancer Active Surveillance Attrition
In a phase 2 trial, use of the novel oral antiandrogen apalutamide shows promise in patients with very low- to intermediate-risk prostate cancer on active surveillance.
-
Loading...
-
Loading...
Next post in Prostate Cancer
